Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) is a progressive and life-threatening illness. According to the WHO, the burden of the disease will increase in the coming decades due to exposure to risk factors (such as smoking), population growth, and aging, and it will become the third cause of mortality by 2030.[@CIT0001],[@CIT0002] In 2016, according to the Global Burden of Disease Study, the incidence of COPD worldwide was 251 million. However, 3.71 million COPD-associated deaths occurred throughout the world in 2015.[@CIT0003]

Based on the available statistics, on average, 10% of Iranians are suffering from COPD, which varies from 1% to 40% in different communities with different climatic conditions.[@CIT0004] The prevalence of COPD is augmenting day by day, while there is no definitive treatment;[@CIT0005] however, the signs and symptoms can be relieved, and life quality can be ameliorated by treatment, thereby reducing hospitalization and death rates.[@CIT0006] The inhalers such as bronchodilators and anti-inflammatory drugs are the main treatments in patients with COPD, while oral medications such as theophylline are only occasionally used, hence the importance of sprays in managing the disease.[@CIT0007]

In spite of the importance of taking medication, research has shown that people have currently problems adhering to their drug regimens.[@CIT0008],[@CIT0009] Various studies have indicated that adherence to the prescribed regimen regarding disorders such as COPD and asthma is at most 50%.[@CIT0010] Factors such as age, disease-related variables (duration, severity), and disease understanding affect adherence to inhalers.[@CIT0011]--[@CIT0015]

Non-adherence to the treatment regimen is a major obstacle in the health system, with ramifications such as disease recurrence, frequent admissions, and more medications, accompanied by increased health care costs.[@CIT0003],[@CIT0016] Non-adherence to medication regimen has various reasons such as the multiplicity of drugs used by patients, concerns about the side effects of medication, misunderstanding the benefits of drugs, and forgetfulness.[@CIT0017],[@CIT0018] In a qualitative study performed in Pakistan, barriers to medication adherence were identified as patient behavior, comorbidity and pill burden, cost-related non-adherence, and low levels of knowledge.[@CIT0019]

Adherence is a behavioral process, as decision-making towards taking or non-taking medicine can be considered as a behaviour.[@CIT0020] The first step in understanding adherence is its evaluation, hence the necessity of valid, reliable, and cost-effective tools accepted by both health care providers and patients. The widespread use of such tools in different societies can provide a better understanding of adherence-related variables, non-adherence, and basis for interventions to ultimately increase the adherence to therapies.[@CIT0021]

Self-reporting questionnaires are currently the most common and cost-effective tools.[@CIT0020] However, they are rarely used in clinics due to their inadequate validity, particularly for inhalers.[@CIT0022]

Commonly employed, inhalers are a major component of drug therapy in patients with COPD, whose correct usage is of great importance. Therefore, as concerns measuring the adherence of patients to inhalers, the general adherence to medication assessment tools is not appropriate given the manner of their use, hence the need for a specific instrument for inhalers. TAI is a tool specifically designed in this area.

Therefore, the researchers decided to assess the validity and reliability of the Farsi version of TAI in COPD patients.

Materials And Methods {#S0002}
=====================

Study Design And Patients {#S0002-S2001}
-------------------------

This is a cross-sectional study conducted for a cultural adaptation of the Persian version of TAI. Participating in the research were 100 patients with COPD referred to Amir-al-Momenin and Vali-Asr educational hospitals in Arak, Iran. All patients were under treatment by two pulmonologists.

This work was supported by the Office of the Vice Chancellor for Research, Arak University of Medical Sciences (IR) under Grant 2825. The Ethics Committee of Arak University of Medical Sciences further approved this project by IR.ARAKMU.REC.1396. 135.

Test Of Adherence To Inhalers (TAI) {#S0002-S2002}
-----------------------------------

TAI was designed and validated by researchers in the Spanish Society of Pulmonology and Thoracic Surgery during an accurate research process. This self-report tool is suitable for daily use in clinical practice owing to its ease of use and the low amount of time required for completion.[@CIT0022] In a study, it became clear that TAI can be used to identify the types of drug non-adherence in COPD patients to plan comprehensive interventions and correct the identified deficiencies.[@CIT0006]

This questionnaire has two forms, the first type being a 10-item questionnaire completed by the patient, identifying the patient's adherence status ranging from poor adherence to optimal adherence. There is also a 12-item questionnaire containing 2 other questions answered by health care providers. If the questionnaire is aimed to check the degree of compliance, the 10-item form is used, and in the case of determining the pattern and type of non-compliance, the 12-item form is employed. In the present study, as in the research of Tegegn and Ayele (2017), the 10-item form was examined.[@CIT0023]

The 10-item form is scored from 1 (the poorest) to 5 (the best) for each item, and the total score of the questionnaire ranges from 10 to 50 (the score of 45 or less indicates poor adherence, 46 to 49 is intermediate adherence, and 50 indicates good adherence).

Translation {#S0002-S2003}
-----------

The tool was translated separately by two translators fluent in English. During a session, the translated tools were compared to conclude a general result, where a single translation was prepared. Two experts checked the accuracy of the translated tool and made the necessary changes. The translated tool was then re-translated to English by a translator fluent in English and compared with the original text. The translated tool was reviewed and approved by the researchers.

Psychometric Properties Of The Instrument {#S0002-S2004}
-----------------------------------------

Face validity, content validity, and concurrent validity were assessed to validate the tool. To test the reliability and internal consistency, the test--retest and Cronbach's alpha were employed, respectively.

Face validity was assessed by 10 patients and 5 specialists.[@CIT0024] The translated questionnaire was primarily provided to 10 hospitalized patients with COPD to complete based on the description provided by one of the researchers; the patients shared their opinions with the researchers regarding the comprehensibility and possible misunderstandings associated with the questions. After that, the tool was given to five experts to confirm the concept and the correctness of the items; their opinions were then applied. The experts were nursing educators, pharmacologists, and pulmonologist who were accessed in their work place.

Content validity was determined by 10 experts. First, the content validity ratio (CVR) was specified based on the Lawshe criteria. Considering the number of contributor experts, the ratio of 64% was considered as appropriate.[@CIT0025] Next, the content validity index (CVI) was scored by 10 experts based on Waltz and Basel indicators (relevance, clarity, and fluency). In this method, the items with a score of over 0.79 are appropriate, those between 0.79 and 0.70 are to be corrected, and the scores less than 0.70 are unacceptable.[@CIT0026]--[@CIT0028]

Concurrent validity was specified by TAI questionnaire and General Medication Adherence Scale (GMAS). GMAS is developed by Naqvi et al (2018). Its content validity index (CVI) was reported 0.8 and Cronbach's alpha 0.84. The test--retest Pearson's correlation coefficient was reported 0.996 (p-value \<0.01). Also, in another study to translate and validate GMAS, its internal consistency was 0.82 and the tool established convergent, discriminant, and concurrent validities. The two scales were completed simultaneously by the patients and the correlation between the results of the two questionnaires was further examined.[@CIT0029],[@CIT0030]

For Cronbach's alpha, the tool was completed by 30 patients, and the Cronbach's alpha was calculated for each item as well as for the whole instrument. The Cronbach's alpha over 0.70 was considered as appropriate.[@CIT0026],[@CIT0031]

In test--retest, the questionnaire was completed by the 10 patients in two stages within a week. The first stage was done face to face and the second stage by telephone. Pearson correlation coefficient and intra-class correlation coefficient (ICC) were determined, with the index higher than 0.8% considered as desirable.[@CIT0032]--[@CIT0034]

Following the translation and psychometric evaluation of the scale and the preparation of the correct version of the Farsi scale, 100 patients were studied by the scale to evaluate their inhaler medication adherence.

The research was conducted after obtaining permission from the original designer of the questionnaire (Plaza et al) and written informed consent of all the participants in the study; this study was conducted in accordance with the Declaration of Helsinki.[@CIT0035]

Results {#S0003}
=======

Validity {#S0003-S2001}
--------

### Face Validity {#S0003-S2001-S3001}

The translated questionnaire had a good face validity after applying the opinions of the patients and specialists.

### Content Validity {#S0003-S2001-S3002}

The content validity ratio and the content validity index of the tool are shown in [Table 1](#T0001){ref-type="table"}.Table 1Content Validity Of The QuestionnaireQuestionCVICVR110.8020.90.80310.80410.8050.70.80610.80710.8081190.90.801010.90Total0.950.83

The CVR and CVI of the whole questionnaire were 0.83 and 0.95, respectively. All the items had good CVR and CVI. [Table 2](#T0002){ref-type="table"} shows the content validity index of the questionnaire in terms of relevance, clarity, and fluency.Table 2Content Validity Index (Relevancy, Clarity, And Fluency)QuestionFluencyClarityRelevancy10.80.912110.930.90.9140.90.9150.90.90.76111711180.90.9190.80.80.910111Total0.920.930.95

### Concurrent Validity {#S0003-S2001-S3003}

The results of the concurrent validity of the instrument together with GMAS are presented in [Table 3](#T0003){ref-type="table"}, where there is a moderate correlation between the two questionnaires which is not significant (r= 0.613, p= 0.06).Table 3Concurrent Validity Of TAI & GMASTAI\
GMASCorrelationCorrelation Coefficient0.613p-value0.06

Reliability {#S0003-S2002}
-----------

[Table 4](#T0004){ref-type="table"} presents the results of the Pearson correlation coefficient and the ICC and Cronbach's alpha of the questions and the whole instrument. The results show that in test--retest, the Pearson correlation coefficient of the questions ranged between 0.822 and 0.939, averaging 0.986 for the whole questionnaire. The ICC of the questions ranged from 0.819 to 0.939, averaging 0.972 for the whole questionnaire. The Cronbach's alpha of the questions varied from 0.901 to 0.968, with an average of 0.986 for the whole questionnaire.Table 4Reliability Measures Of TAIVariableFirst TestSecond TestPaired *t*-TestPearson Correlation CoefficientInterclass Correlation (ICC)p-ValueCronbach AlphaMean (SD)Mean (SD)p-ValuetTest MeansOne Test\*Q11.05 (2.09)1.04 (2.02)0.210−1.2610.8600.9250.8600.00010.925Q21.32 (3.29)1.31 (3.3)0.897−0.130.8290.8590.9070.00010.907Q31.28 (2.58)1.39 (2.7)0.140−1.4860.8220.8190.9010.00010.901Q41.06 (3.75)1.06 (3.81)0.222−1.2280.8950.8950.9440.00010.944Q51.43 (3.46)1.41 (3.34)0.052.0310.9140.9140.9550.00010.955Q61.14 (3.82)1.15 (3.84)0.62−0.4980.9390.9390.9680.00010.968Q71.20 (3.89)1.23 (3.9)0.829−0.2170.9290.9290.9630.00010.963Q81.34 (3.59)1.34 (3.58)0.259−1.1360.9230.9230.9600.00010.960Q91.1 (3.73)1.15 (3.67)0.2591.1360.8920.8910.9420.00010.942Q101.12 (3.82)1.09 (3.88)0.259−1.1360.8870.8860.9400.00010.940Total6.002 (33.95)6.22 (34.04)0.32−0.6270.9730.9720.9860.00010.986

Pilot Study {#S0003-S2003}
-----------

100 patients were evaluated by the scale. The mean (SD) age was 53 (6.17) years. 57% of study participants were male and 31% had high school education. The demographic characteristics of the patients are presented in [Table 5](#T0005){ref-type="table"}.Table 5Demographic Characteristics Of Study ParticipantsCharacteristicsFrequencyPercentGenderMale5757Female4343Marital statusSingle11Married8282Divorced88Widow99Educational levelIlliterate88Elementary school2626High school1919College graduate3131Higher education1616OccupationHousewife3232Clerk66Worker2020Self-employed3333Other99DiagnosisEmphysema2525Bronchitis4242Both3333ComorbidityHTN3232Diabetes2323Multiple Sclerosis55Cancer99No disease3131Smoking historyYes8686No1414Age, yearsMean (SD)53 (6.17)

The adherence to medication rate of patients is provided in [Table 6](#T0006){ref-type="table"}, where most had a poor medication adherence, probably due to the high cut off presented for TAI. Based on the statistical analysis, there was no relationship between the demographic characteristics of the patients and their medication adherence.Table 6Patient Adherence To MedicationFrequency\
Adherence LevelRelativeAbsolutePoor9999Intermediate11Total100100

[Table 7](#T0007){ref-type="table"} indicates some information about the item scores.Table 7The Information About The Item ScoresAlwaysMore Than HalfAbout HalfLess Than HalfNoneRangeMedianQ110251574332AlwaysMostlySometimesRarelyNeverQ2131328232343Q324319231342Q43922363044Q5141816242844Q65821303644Q79512353944Q813914352944Q931622293044Q1021315353544

Discussion {#S0004}
==========

It is believed that lack of adherence by patients is a serious global health problem affecting all areas, cultures, ages, and diseases. This problem has remained unchanged over the past 30 years. The poor treatment adherence of the patients ensues higher mortality, frequent attacks, poorer control, and higher social and economic costs, particularly concerning diseases such as asthma and COPD. The clinical significance of this issue has led to guidelines for identifying and then modifying poor treatment adherence. Given that the main treatment of these patients is through inhalers, a tool is required to check adherence to inhalers.[@CIT0036]

The present cross-sectional study focused on the translation and psychometry of TAI. The results showed that the Farsi version of TAI has good validity and reliability. In determining the validity of the tool, it was observed that all items had a CVR ranging from 0.8 to 1, and a CVI varying from 0.7 to 1, which is acceptable. The designers of this questionnaire further concluded that TAI has good psychometric properties, and is suitable for assessing medication adherence regarding asthma and COPD patients.[@CIT0022] To evaluate the concurrent validity of the TAI tool, GMAS was considered, where a moderate but not significant correlation was observed between the two questionnaires (r= 0.613, p= 0.06). In their study on compliance with inhalers in the COPD patients from seven Latin American countries, Montes de Oca et al (2017) made use of TAI and Morisky questionnaires, observing that the coefficient of agreement between the two questionnaires was moderate (Kappa index: 0.42; agreement: 64.7%).[@CIT0037] In Spain, a multiple study was conducted to combine the results of the TAI tool and electronic registry recording of drugs used to improve the understanding of medication adherence status. In this research, however, the results of the preliminary study, done on a limited number of samples, showed that the information obtained by the TAI was valid in contrast to the information associated with the electronic registry.[@CIT0036]

In determining the reliability of the tool, it was observed that in the test--retest, the correlation coefficient of the whole questionnaire was 0.973, the ICC was 0.972, and Cronbach's alpha was 0.986, all of which are acceptable. The designers of the questionnaire further conclude that the tool has excellent internal validity (Cronbach's alpha = 0.873) and appropriate test--retest reliability (ICC = 0.883).[@CIT0036]

The pilot study showed poor medication adherence, probably, due to the high cut off the original study (Plaza et al). If the cut off was considered lower, medication adherence scores might be better.

Limitations {#S0005}
===========

In the test--retest, the first stage of instrument completion was performed in the presence of the patients; the second stage, on the other hand, was conducted via telephone calls due to lack of access to the patients, which might limit the accuracy of responses by the patients.

Conclusion {#S0006}
==========

It is highly important to have a valid and reliable tool to assess the adherence to inhalers, especially in COPD patients. In this regard, TAI is a tool designed by Plaza et al for this purpose. The present study aimed to translate and determine the psychometric properties of the tool to provide an effective step towards identifying the patient adherence to medication status and planning for their medication adherence. The results showed that the Farsi version of the tool has good validity and reliability; however, the result of concurrent validity needs more studies. TAI seems a suitable, accessible, and inexpensive tool for daily use in clinical practice.
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